Author/Authors :
Alizadeh Ghavidel، Alireza نويسنده , , Nabavi، Salaheddin نويسنده Cardiac Surgery Fellow, Heart Valve Disease Research Center AND Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran , , Haghjoo، Majid نويسنده Echocardiography Research Center, Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran. , , Toutonchi، Zia نويسنده Associate Professor, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran , , Mirmesdagh، Yalda نويسنده Rajaei Cardiovascular, Medical and Research Center, Tehran University of Medical Sciences, Tehran, Iran. , , Javadikasgari، Hoda نويسنده Research Fellow, Heart Valve Disease Research Center AND Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran ,
Abstract :
BACKGROUND: Reperfusion ventricular fibrillation after aortic cross clamp is one of the
important complications of open cardiac surgery and its prevention could reduce myocardial
injuries. This study aimed to evaluate the efficacy of single dose of amiodarone or lidocaine by
the way of pump circuit three minutes before aortic cross clamp release and compare the results
with normal saline as placebo in a randomized double blinded controlled trial.
METHODS: One hundred fifty patients scheduled for first time elective coronary artery bypass
graft surgery were randomly assigned to receive either single dose of amiodarone (150 mg),
lidocaine (100 mg), or normal saline (5 ml) three minutes before aortic cross clamp release. The
incidence of ventricular fibrillation and the need for reuse of drug were compared between these
groups by chi-square, Student’s t-test, Mann-Whitney test, and One-way ANOVA. SPSS software
was used for statistical analysis.
RESULTS: The incidence of ventricular fibrillation is higher in the placebo group (15.9%)
compare to lidocaine (11.8%) and amiodarone (8.9%) groups; however, there was no statistical
difference among the three groups (P = 0.41). Moreover, the reuse of amiodarone (22.7%) was
statistically higher (P < 0.05) than lidocaine (5.9%).
CONCLUSION: This study showed no difference among lidocaine, amiodarone, and placebo in
preventing ventricular fibrillation after aortic cross clamp release.